Dianthus Therapeutics (DNTH) Stock Price Target 2026

The average analyst price target for Dianthus Therapeutics is $128.44, 49.7% above the current price. Of 19 analysts, 19 rate it Buy. Targets range from $65 to $200. The latest change came on Oct 27, 2026, when Roth Capital initiated coverage of Dianthus Therapeutics with a Buy rating and a $113 price target.

The Average Analyst Price Target for Dianthus Therapeutics is $128.44.

Price Target Range — 13 Quarters

Analyst Consensus — 19 Analysts

1S.Buy

18Buy

Consensus RatingBuy# Analysts19Avg. Consensus PT$128.44Upside to Avg. PT+49.7%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Dianthus Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	Roth Capital	Adam Walsh	Initiate	Buy	$113
Oct 15, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$158
Sep 11, 2026	JP Morgan	Brian Cheng	Initiate	Overweight	$135
Sep 4, 2026	Citigroup	Samantha Semenkow	Initiate	Buy	$156
Aug 6, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$110→$128
Aug 6, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$130→$158
Aug 5, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$105→$122
Aug 3, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$120→$134
May 6, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$103→$105
Apr 9, 2026	Wolfe Research	Andy Chen	Initiate	Outperform	$98
Mar 19, 2026	Wells Fargo	Sadia Rahman	Initiate	Overweight	$135
Mar 12, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$80→$103
Mar 10, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$55→$80
Mar 10, 2026	Raymond James	Steven Seedhouse	Upgrade	Outperform→Strong Buy	$63→$123
Mar 10, 2026	Baird	Joel Beatty	PT Raise	Outperform	$67→$132
Mar 10, 2026	Clear Street	Bill Maughan	PT Raise	Buy	$100→$130
Mar 9, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$47→$130
Mar 9, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$125→$145
Mar 9, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$63→$110
Mar 4, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$100→$200

Analyst Ratings News

This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts initiated Buy coverage on DRIO ($6), WATT ($15), PPL ($41), DNTH ($113); PYPD rated Outperform with a $10 target.

Avi Kapoor

PRO
Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113

Roth Capital analyst Adam Walsh initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $113.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and maintains $158 price target.

Benzinga Newsdesk

This Shopify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Wall Street analysts initiated coverage on PPG, Shopify, Chesapeake Utilities, Global Payments and Dianthus, with targets ranging from $101 to $160.

Avi Kapoor

PRO
JP Morgan Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135

JP Morgan analyst Brian Cheng initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Overweight rating and announces Price Target of $135.

Benzinga Newsdesk

PRO
Citigroup Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $156

Citigroup analyst Samantha Semenkow initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $156.

Benzinga Newsdesk

Dianthus Therapeutics Inc

Dianthus Therapeutics (DNTH) Stock Price Target 2026

The Average Analyst Price Target for Dianthus Therapeutics is $128.44.

Latest Upgrades and Downgrades for Dianthus Therapeutics Stock

Analyst Ratings News

This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRO
Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113

PRO
HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Target

This Shopify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
JP Morgan Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135

PRO
Citigroup Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $156

People Also Watch

People Also Watch

Dianthus Therapeutics Inc

Dianthus Therapeutics (DNTH) Stock Price Target 2026

The Average Analyst Price Target for Dianthus Therapeutics is $128.44.

Latest Upgrades and Downgrades for Dianthus Therapeutics Stock

Analyst Ratings News

This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRORoth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113

PROHC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Target

This Shopify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PROJP Morgan Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135

PROCitigroup Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $156

People Also Watch

People Also Watch

PRO
Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113

PRO
HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Target

PRO
JP Morgan Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135

PRO
Citigroup Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $156